Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Fiche publication

Date publication

mai 2026

Journal

Cancer immunology, immunotherapy : CII

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Amrane K, Campedel L, Moinard-Butot F, Gout M, Mahammedi H, Bennamoun M, Herrmann T, Gabriel PE, Pouessel D, Roulleaux-Dugage M, Thibault C, Cancel M, Flechon A, Huillard O, Abbar B, Borchiellini D, Doublet L, Augusto-Pelegrin L, Boughalem E, Cornillon P, Dumont C, Barthélémy P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42177701

Résumé

Histologic variants (HV) of urothelial carcinoma (UC-V) and non-urothelial carcinomas (NUC) of the bladder and urinary tract are aggressive malignancies with poor prognosis and limited response to platinum-based chemotherapy. Despite their biological particularities and distinct immune microenvironments, these HV subtypes are under-represented in immune checkpoint blockade (ICB) trials.